EVALUATION OF THE HTA CORE MODEL FOR NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS: COMPARATIVE STUDY AND EXPERIENCES FROM EUROPEAN COUNTRIES

被引:9
|
作者
Korge, Kristina [1 ]
Berndt, Nadine [2 ]
Hohmann, Juergen [3 ]
Romano, Florence [2 ]
Hiligsmann, Mickael [4 ]
机构
[1] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[2] Inspect Gen Securite Sociale, Cellule Expertise Med, Luxembourg, Luxembourg
[3] European Commiss, Migrat Employment & Inequal, DEVCO B3, Brussels, Belgium
[4] Maastricht Univ, Sch Publ Hlth & Primary Care, Dept Hlth Serv Res, Maastricht, Netherlands
关键词
Technology assessment; Validation studies; Case reports; Qualitative research; National health policy;
D O I
10.1017/S026646231700099X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: The health technology assessment (HTA) Core Model (R) is a tool for defining and standardizing the elements of HTA analyses within several domains for producing structured reports. This study explored the parallels between the Core Model and a national HTA report. Experiences from various European HTA agencies were also investigated to determine the Core Model's adaptability to national reports. Methods: A comparison between a national report on Genetic Counseling, produced by the Cellule d'expertise medicale Luxembourg, and the Core Model was performed to identify parallels in terms of relevant and comparable assessment elements (AEs). Semi-structured interviews with five representatives from European HTA agencies were performed to assess their user experiences with the Core Model. Results: The comparative study revealed that 50 percent of the total number (n = 144) of AEs in the Core Model were relevant for the national report. Of these 144 AEs from the Core Model, 34 (24 percent) were covered in the national report. Some AEs were covered only partly. The interviewees emphasized flexibility in using the Core Model and stated that the most important aspects to be evaluated include characteristics of the disease and technology, clinical effectiveness, economic aspects, and safety. Conclusions: In the present study, the national report covered an acceptable number of AEs of the Core Model. These results need to be interpreted with caution because only one comparison was performed. The Core Model can be used in a flexible manner, applying only those elements that are relevant from the perspective of the technology assessment and specific country context.
引用
收藏
页码:644 / 653
页数:10
相关论文
共 50 条
  • [21] Using real-world data (RWD) in health technology assessment (HTA) practice: A comparative study of 5 HTA agencies
    Makady, Amr
    van Veelen, Ard
    Jonsson, Pall
    Moseley, Owen
    D'Andon, Anne
    de Boer, Anthonius
    Hillege, Hans
    Klungel, Olaf
    Goettsch, Wim
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 91 - 91
  • [22] USING REAL-WORLD DATA (RWD) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) PRACTICE: A COMPARATIVE STUDY OF 5 HTA AGENCIES
    Makady, A.
    van Veelen, A.
    Jonsson, P.
    Moseley, O.
    D'Andon, A.
    de Boer, A.
    Hillege, J. L.
    Klungel, O.
    Goettsch, W.
    VALUE IN HEALTH, 2017, 20 (09) : A401 - A401
  • [23] SPECIAL CONSIDERATIONS AND PATIENT ACCESS SCHEMES FOR ONCOLOGY BY HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES: SYSTEMATIC EVALUATION IN 25 COUNTRIES
    Mwamburi, M.
    Nanavaty, M.
    Gala, S.
    Nyandege, A.
    Ramesh, V
    VALUE IN HEALTH, 2016, 19 (07) : A761 - A761
  • [24] Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey
    Zoltan Vokó
    Kei Long Cheung
    Judit Józwiak-Hagymásy
    Silke Wolfenstetter
    Teresa Jones
    Celia Muñoz
    Silvia M.A.A. Evers
    Mickaël Hiligsmann
    Hein de Vries
    Subhash Pokhrel
    Health Research Policy and Systems, 14
  • [25] Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey
    Voko, Zoltan
    Cheung, Kei Long
    Jozwiak-Hagymasy, Judit
    Wolfenstetter, Silke
    Jones, Teresa
    Munoz, Celia
    Evers, Silvia M. A. A.
    Hiligsmann, Mickael
    de Vries, Hein
    Pokhrel, Subhash
    HEALTH RESEARCH POLICY AND SYSTEMS, 2016, 14
  • [26] POLICIES FOR USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT: A COMPARATIVE STUDY OF 6 HTA AGENCIES
    Makady, A.
    ten Ham, R.
    de Boer, A.
    Hillege, J. L.
    Klungel, O.
    Goettsch, W.
    VALUE IN HEALTH, 2016, 19 (07) : A501 - A502
  • [27] THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH TECHNOLOGY ASSESSMENT (HTA) OF VACCINES-LESSONS LEARNED FROM FINLAND
    Laine, J.
    Soini, E. J.
    Martikainen, J. A.
    VALUE IN HEALTH, 2009, 12 (07) : A432 - A432
  • [28] PROVISIONS AND SPECIAL CONSIDERATIONS FOR RARE DISEASES / ORPHAN DRUGS BY HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES: SYSTEMATIC EVALUATION IN 25 COUNTRIES
    Mwamburi, M.
    Nanavaty, M.
    Gala, S.
    Nyandege, A.
    Ramesh, V
    VALUE IN HEALTH, 2016, 19 (07) : A602 - A602
  • [29] Untangling the Complexity of Funding Recommendations: A Comparative Analysis of Health Technology Assessment Outcomes in Four European Countries
    Cerri K.H.
    Knapp M.
    Fernandez J.-L.
    Pharmaceutical Medicine, 2015, 29 (6) : 341 - 359
  • [30] EVALUATION OF THE EXTENT OF REAL-WORLD EVIDENCE (RWE) USED WITHIN HEALTH TECHNOLOGY APPRAISALS (HTA) IN ONCOLOGY: A COMPARATIVE STUDY OF SIX HTA AGENCIES
    Harricharan, S.
    Curran, E.
    Lin, H. M.
    Walton, L. J.
    Gurjar, K.
    Nguyen, K.
    Forsythe, A.
    VALUE IN HEALTH, 2021, 24 : S44 - S44